{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-023584","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.569011+00:00","generated_at":"2026-06-04T14:35:00.952076+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Oramed appoints Yehuda Reznick as director and audit committee chair effective April 1, 2024","bullets":["Yehuda Reznick appointed to fill existing board vacancy; also audit committee chair and designated financial expert.","Reznick, 76, was an audit partner at Kesselman & Kesselman (PwC affiliate) from 1999 to 2014.","Compensation same as other non-executive directors; standard indemnification agreement expected.","Currently serves on board of Oravax Medical Inc., an affiliate of Oramed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-023584","json":"https://secwatch.observer/filing/0001213900-24-023584.json","markdown":"https://secwatch.observer/filing/0001213900-24-023584.md","text":"https://secwatch.observer/filing/0001213900-24-023584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024023584/0001213900-24-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024023584/ea0201979-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:35:00.952076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cf53ce72a","claim":"Yehuda Reznick was appointed as director at ORAMED PHARMACEUTICALS INC..","evidence_excerpt":"On March 12, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Yehuda Reznick to serve as a director, effective as of April 1, 2024, to fill an existing vacancy on the board of directors (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024023584/0001213900-24-023584-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}